胃肠道外间质瘤临床病理特征、治疗方法对预后的影响  

Effect of clinicopathological features and therapeutic methods on prognosis in extra-gastrointestinal stromal tumor

作　　者：刘立成 刘雅刚[1] 徐文通[2] LIU Licheng;LIU Yagang;XU Wentong(Department of General Surgery,Center Hospital of Cangzhou,Hebei Cangzhou 061000,China;Department of General Surgery,General Hospital of PLA,Beijing 100853,China)

机构地区：[1]沧州市中心医院普通外科,河北沧州061000 [2]中国人民解放军总医院普通外科,北京100853

出　　处：《现代肿瘤医学》2021年第9期1556-1559,共4页Journal of Modern Oncology

摘　　要：目的:分析胃肠道外间质瘤(extra-gastrointestinal stromal tumors,EGIST)的临床特征、手术方式和伊马替尼治疗对患者生存率的影响。方法:回顾性总结2010年01月至2018年12月我院收治的40例胃肠道外间质瘤患者的临床资料。计量和计数资料分别采用t检验和χ^(2)检验,生存情况采用寿命表法和Kaplan-Meier法。结果:全组胃肠道外间质瘤(EGIST)患者术后中位随访时间为24个月(3~76个月),1、3、5年生存率分别为75%、42%、35%。R0术后服用伊马替尼组3例患者1、2、3生存率100%、100%、100%;R0术后未服用伊马替尼组14例患者1、2、3生存率100%、91.0%、91.0%;非R0术后服用伊马替尼组12例患者1、2、3生存率91.7%、50.3%、33.5%;非R0术后未服用伊马替尼组11例患者1、2、3年生存率18.2%、9.0%、0;差异有统计学意义(P=0.000)。结论:EGIST具有低的发病率,预后差。手术方式、肿瘤是否破裂、有无复发转移、危险度分级、术后靶向药物治疗等是影响EGIST预后的重要因素。Objective:To analyze the clinical characters,survival rates of extra-gastrointestinal stromal tumors(EGIST)and surgical treatment or imatinib therapy to the influence of survival time.Methods:The clinical data of 40 patients with extra-gastrointestinal stromal tumors who were admitted to our hospital from January 2010 to December 2018 were retrospectively analyzed.All data were analyzed using the t test and chi-square test,and the survival rate of patients was analyzed using the life table and Kaplan-Meier curves.Results:All patients were followed up with the median time of 24 months(3 to 76 months).The over survival rates(OS)of 1-year,3-year,5-year were 75%,42%and 35%in the all patients.The survival rates of 1-year,2-year,3-year in the group of receiving R0 resection and imatinib mesylate(3 cases)were 100%,100%and 100%respectively.The survival rates of 1-year,2-year,3-year in the group of receiving R0 resection without imatinib mesylate(14 cases)were 100%,91.0%and 91.0%,respectively.The survival rates of 1-year,2-year,3-year in the group of receiving non R0 resection with imatinib mesylate(12 cases)were 91.7%,50.3%and 33.5%,respectively.The survival rates of 1-year,2-year,3-year in the group of receiving non R0 resection without imatinib mesylate(11 cases)were 18.2%9.0%and 0,respectively.These differences had obvious statistical significance between these groups(P=0.000).Conclusion:EGIST has low morbidity and poor prognosis.The resection mode,rupture of tumors,recurrence and metastasis,NIH and targeting therapy are important factors affecting the prognosis of EGIST.

关 键 词：胃肠外间质瘤 治疗 病理 预后 

分 类 号：R735.2[医药卫生—肿瘤]